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Chronic or recurrent inflammation plays a role in the development of many types of cancer including prostate cancer. CXCL10 (interferon-γ
inducible protein-10, IP-10) is a small secretory protein of 8.7 kDa. Recently, it has been shown that normal prostate epithelial (PZ-HPV-7)
cells produce lower amounts of angiogenic CXC chemokines (GRO-α, IL-8) and higher amounts of angiostatic chemokines (CXCL10,
CXCL11) as compared to prostate cancer cells (CA-HPV-10 and PC-3). Accordingly, we studied the effects of overexpression of CXCL10 in
human prostate cancer LNCaP cells. LNCaP cells were transiently transfected with CXCL10 cDNA in pIRES2-EGFP vector. CXCL10,
CXCR3, PSA and G3PDH mRNA levels were determined by semi-quantitative conventional and quantitative real-time RT-PCR and
fluorescence-activated cell sorting (FACS). The expression of CXCL10 was markedly enhanced in the transfected cells at mRNA and protein
levels in the cells. Overexpression of CXCL10 inhibited cell proliferation of the transfected cells by 30%–40% in serum-limited medium (1%
FCS in RPMI1640 medium) and decreased PSA production. CXCR3 expression was significantly induced by the overexpression of CXCL10
as determined by RT-PCR and FACS. These results indicated that CXCL10 inhibited LNCaP cell proliferation and decreased PSA production
by up-regulation of CXCR3 receptor. CXCL10 may be potentially useful in the treatment of prostate cancer.
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Prostate cancer is the most commonly diagnosed cancer
among men in the Western countries. Genes, dietary factors and
lifestyle-related factors contribute to the development of
prostate cancer. The initial growth of prostate cancer is usually
androgen-dependent, but subsequently becomes androgen-
independent over time when treated with androgen-deprivation
therapy [1]. It has been recently suggested that the changes in
the androgen receptor non-genomic signaling pathway may⁎ Corresponding author. University of South Carolina School of Medicine,
Medical Library Building, Suite 316, Columbia, SC 29209, USA. Fax: +1 803
733 1547.
E-mail address: lin@gw.med.sc.edu (T. Lin).
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doi:10.1016/j.bbadis.2006.06.017play an important role in the progression of human prostate
cancer to androgen-independence [2,3].
Chronic or recurrent inflammation is associated with
development of many human cancers, including cancer of the
liver, stomach, intestine, bladder and prostate [4]. In the tumor
bed, cytokines are secreted by both tumor-infiltrating immune
cells and by the tumor cells themselves, and these cytokines can
have pleiotropic effects. The intratumoral injection of CXCL10
improved long-term survival of severe combined immune
deficiency (SCID) mice with non-small cell lung cancer [5].
Intratumoral/intraperitonial administration of only 3×107
replication units of MV/Mp/CXCL10 per animal strongly
inhibited the progression of established polyoma virus middle
T antigen (HSV)-vascular tumors [6]. Moreover, high affinity
binding sites for CXCL10 have been reported on in vitro
cultured normal lung epithelial and lung cancer cells [7]. In the
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Leydig cells [8,9]. Its expression is inhibited by human
chorionic gonadotropin (hCG), but induced by murine inter-
feron-γ (mIFN-γ), murine interleukin-1α (mIL-1α) and murine
tumor necrosis factor-α (mTNF-α). It was further demonstrated
that CXCL10 has a strong inhibitory effect on steroidogenesis
[8]. Recently, it has been shown that normal prostate epithelial
(PZ-HPV-7) cells produce lower amounts of angiogenic CXC
chemokines (GRO-α, IL-8) and higher amounts of angiostatic
chemokines (CXCL10, CXCL11) as compared to prostate
cancer cells (CA-HPV-10 and PC-3) [10]. Accordingly, we
studied the effects of overexpression of CXCL10 in human
prostate cancer LNCaP cells.
2. Materials and methods
2.1. Materials
Human CXCL10 immunoassay kit, phycoerythrin-CXCR3 Ab and goat
antihuman CXCL10 Ab were purchased from www.RnDSystems.com.
RPMI1640, fetal calf serum (FCS), Trizol reagent, oligo-dT primer, Super-
scriptIII and enzymes were procured from www.invitrogen.com. Charcoal
stripped FCS (CS-FCS) was obtained from www.BioMeda.com. EndoFree
PlasmidMaxi Kit was obtained from www.qiagen.com. FUGENE 6 reagent was
purchased from www.roche-applied-science.com. Mibolerone (Mib) a non-
metabolizable synthetic androgen, was purchased from http://las.perkinelmer.
com. RT-PCR reagents and MTS assay kit were purchased from www.Promega.
com, and Real-Time PCR reagents including SYBR Green reagent were
purchased from www.discover.bio-rad.com. Anti-goat secondary Alexa594
conjugate and rhodamine phalloidin were obtained from Molecular Probes
(Eugene, OR). Draq5 (nuclear stain) was obtained from www.alexis-e.biz. and
pIRES2-EGFP vector from www.bdbiosciences.com.
2.2. Cell culture
LNCaP cells were obtained from American Type Culture Collection (www.
atcc.org). LNCaP cells were cultured in RPMI1640 supplemented with 5% FCS
and 1% antibiotic penicillin and streptomycin. The cells were maintained under
standard cell culture conditions at 37 °C and 5% CO2 in a humid environment
until reaching ∼50–70% confluence.
2.3. Treatment of cells
The medium was changed to serum-free RPMI 1640 to deplete undesired
steroids for 4 h prior to experiments. Cells were then treated with RPMI 1640
containing FCS (1%–5%) or CS-FCS (1%) with/without mibolerone (Mib) (1–
100 nM). Mib was dissolved in dimethyl sulfoxide (DMSO). The final
concentration of DMSO was 0.1% for each treatment. Equivalent amounts of
solvent were added to control cells.
2.4. Cell proliferation assay
LNCaP cells were seeded at 2×103 cells/well in 96-well plates. After 72 h,
they were treated with serum-free RPMI 1640 for 4 h and incubated with varying
amounts of FCS, CS-FCS with/without 1 nM Mib. An MTS assay was
performed using a Microplate Reader (www.discover.bio-rad.com). Four wells
per treatment were used for the assays and each experiment was repeated thrice.
2.5. Cloning the human CXCL10 gene in a mammalian
high-expression vector
Total RNA was isolated from peripheral blood mononuclear cells (PBMC)
(from a frozen stock) using Trizol reagent. RNAwas treated with ribonuclease-
free DNaseI to remove any contaminating DNA. The published sequence forhuman CXCL10 (GenBank accession number 15012098) was used to derive
PCR primers (sense, 5′-GAAGCTAGC- ATGAAT CAAACTGCCATT CTG
ATT-3′; antisense, 5′-GAC GAATTC- TTA AGG AGATCT TTT AGA CCT
TTC C-3′), incorporating NheI and EcoRI restriction sites.
2.6. Transfection of cells with pIRES2–EGFP–CXCL10
(pI2E–CXCL10)
The pI2E–CXCL10 plasmid DNA was amplified and purified with
EndoFree Plasmid Maxi Kit. Cells were transfected with 10 μg plasmid DNA
in FUGENE 6 reagent for 48 h. The cells were further treated with different
types of media, with or without mib, for various time periods and harvested, and
the medium and harvested cells were stored at −80 °C for further analysis.
2.7. hCXCL10 assay in spent media
Cells were grown for 3 days to 6 days, media were collected, centrifuged and
stored as spent media at − 80 °C until the assays were conducted. The hCXCL10
assays were carried out by the sandwiched enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer's protocol (RNDSystems.com). Briefly,
standards, controls and samples were pipetted into the wells of a microplate pre-
coated with a polyclonal antibody specific for hCXCL10. Any hCXCL10
present was bound by the immobilized antibody. After washing away any
unbound substances, an enzyme-linked polyclonal Ab specific for hCXCL10
was added to the wells. Following a wash, a substrate solution was added. The
enzyme reaction yielded a blue product that turned yellow when the Stop
Solution was added. The intensity of the color measured (at 450 nm and
correction carried out at 540 nm) is in proportion to the amount of hCXCL10
bound in the initial step. The recovery tests were carried out by measuring
hCXCL10 in spent media with or without adding known amounts of rCXCL10.
Standard curve was generated with each set of data.
2.8. Comparative RT-PCR for mRNA expression
cDNA was generated using 5 μg total RNA, 2.5 μg oligo-dT primer and
SuperscriptIII at 42 °C for 1 h. Total cDNA (1/20 of the reaction) was used as the
template for PCR. The amplification reaction buffer also contained 0.2 mM of
each dNTP, 10 pM of each primer, cDNA template and 1.5 U pfu DNA
polymerase. The amplification were carried out on PTC-200 (MJ Research, Inc.,
Waltham, MA). Cycling programs were 94 °C for 2 min, followed by 26–40
cycles of 94 °C for 30 s, 48 °C for 30 s, 72 °C for 1.5 min, with a final extension
of 72 °C for 4 min.
The primers used in this study were synthesized by the Oligonucleotide
Synthesis Core Facility, University of South Carolina, and were as follows:
hG3PDH (gi: 32891804), 5′-GGA AAC TGT GGC GTG CTG G-3′ and
5′-ACT CCC CAG CAG TGA GGG TC-3′, PCR product size 601 bp;
hCXCL10 (gi 15012098), 5′-CTG CCATTC GAT TTG CTG C-3′ and
5′-ACC TTT CCT TGC TAA CTG CT-3′, PCR product size 270 bp;
EGFP (using pIRES2-EGFP sequence ), 5′-GAA GGA AGC AGT TCC
TCT GG-3′ and 5′-TCA TCG TGT TTT TCA AAG GA-3′, PCR product
size 366 bp;
hCXCR3 (gi 31455575), 5′-CTC TGC TGG ACC CCC TAT CA-3′ and
5′-GTC TCA GAC CAG GAT GAATC-3′, PCR product size 283 bp;
hPSA (KLK3 gene) (gi 14422306), 5′-CCT CCT GAA GAA TCG ATT
CCT-3′ and 5′-GAG GTC CAC ACA CTG AAG TT-3′, PCR product size
360 bp.
2.9. Quantitative Real-time PCR for mRNA expression
Real-time quantitative PCR amplification reactions were carried out using
MyiQ system (www.discover.bio-rad.com), which incorporates 96-channel
optical unit. Primers used for PSA amplification were: forward, 5′-ACT CAC
AGC AAG GAT GGA GCT GAA-3′; reverse, 5′-TGA GGG TTG TCT GGA
GGA CTT CAA-3′; PCR product size 197 bp [11] and for hG3PDH were: 5′-
ATC ACT GCC ACC CAG AAG AC-3′ and 5′-GCC ATG CCA GTG AGC
TTC CC-3′; PCR product size 153 bp [12].The reaction mixture consisted of 1 ×
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0.2 mM each dNTP, iTaq DNA polymerase (hot-start enzyme) 25 units/ml,
10 nM SYBR Green, and stabilizers. Fifty nanograms of cDNA template was
added to each reaction. The final volume was adjusted to 20 μl with H2O. The
PCR conditions were: 95 °C, 8:30 min; 48 cycles of 95 °C, 0:30 min; 60 °C,
0:30 min; 72 °C, 1:00 min. To distinguish specific amplicons from non-specific
amplifications, a melt curve was generated. Standard curves were generated for
G3PDH and PSA.
2.10. Detection of protein expression by immunocytochemical analysis
The cells were grown on chamber slides, fixed for 10 min in 4% formalin in
PBS at r.t. The cells were permeabilized in 0.2% Triton-X100 for 3 min at r.t.
The slides were incubated with goat anti-human CXCL10 primary Ab (1:250
dilution). Slides were rinsed twice with PBS and incubated with Alexa594-
conjugated donkey anti-goat Ab (1:1000 dilution). Confocal microscopy was
performed using 40× oil immersion objective using BioRad MRC-1024 Laser
Confocal Microscope. The fluorescence of EGFP, Draq5 and Rhodamine
staining were detected by the confocal microscopy using specific light filters.
2.11. Fluorescence activated cell sorter (FACS) analysis for CXCR3
protein expression
The cells were harvested by mild trypsinization, treated with the
phycoerythrin-conjugated CXCR3 Ab, washed in PBS containing 2% FCS
and resuspended in PBS. The cells were passed through cell strainer (35 μM
nylon mesh) (www.fishersci.com). The single cell suspensions were then
subjected to FACS using a Coulter Epics XL-MCL flow cytometer.
2.12. Statistical analyses
Results are the means±SEM of 4–6 separate experiments. One-way
ANOVA followed by Newman–Keuls multiple comparison tests were used for
statistical analyses (GraphPad Prism, version 3.0; GraphPad Software Inc., San
Diego). P≤0.05 was considered statistically significant.
3. Results
3.1. Overexpression of CXCL10 in LNCaP cells
A complete human CXCL10 cDNAwas generated from the
total RNA isolated from peripheral blood mononuclear cellsFig. 1. Localization of EGFP and CXCL10 in human prostate LNCaP transfected cells
phalloidin (Red; actin stain). (B) Cells transfected with the pI2E–CXCL10 plasmid, an
stain). EGFP fluorescence (Green) is visible in these cells indicating successful transfecti
(goat anti human CXCL10 and Donkey anti goat Alexa 594). The red fluorescence sho
membrane, but not in the nucleus. (For interpretation of the references to colour in thi(PBMC). The PCR product was digested with NheI and EcoRI,
gel purified and cloned into the gel purified NheI and EcoRI
digested pIRES2–EGGP vector. The direction of cloning and
correctness of the sequence were further checked by restriction
mapping and sequencing.
3.2. Localization of CXCL10 in LNCaP cells
Cells were transiently transfected with 10 μg of pI2E–CXCL10
using Fugene6 reagent. CXCL10 expression was visualized by
goat-antihuman CXCL10 Ab and Alexa594-conjugated donkey
anti-goat second Ab by Laser Confocal Microscopy. The nuclear
staining (Blue with Draq5) and actin (red with rhodamine
phalloidin were detected in control (untransfected) (Fig. 1A) and
pII2E–CXCL10 transfected cells (Fig. 1B). Green fluorescence
was detected only in the pI2E–CXCL10 transfected cells (Fig.
1B). The red fluorescence shows the localization of CXCL10 in
pI2E–CXCL10 transfected cells (Fig. 1C). CXCL10 is mainly
localized in the cytoplasm and membrane (Fig. 1C).
3.3. Secretion of CXCL10 by the transfected LNCaP cells
Cells were grown for 3–8 days, media were collected,
centrifuged and stored at −80 °C. The CXCL10 secreted by
transfected cells increased significantly over the growth period
(Fig. 2B). Transfected cells secreted 3–6 ng/ml of CXCL10
after 6–8 days of cell culture, (80%–90% confluent) (n=4),
whereas the control or vector transfected cells secreted no
detectable amounts of CXCL10. The detectable amounts of
CXCL10 by ELISA assay were 0.04–0.06 ng/ml.
3.4. Effect of overexpression of CXCL10 on cell proliferation
There was no significant difference in cell proliferation in
control and pI2E–CXCL10 transfected cells grown in serum-
rich medium (5% FCS) (Fig. 3). However, overexpression of
CXCL10 inhibited cell proliferation of the transfected cells by. (A) Untransfected cells stained with Draq5 (Blue; Nuclear stain) and rhodamine
d stained with Draq5 (Blue; Nuclear stain) and rhodamine phalloidin (Red; actin
on. (C) Cells transfected with the pI2E–CXCL10 plasmid and stained for CXCL10
ws the localization of CXCL10. CXCL10 is mainly localized in the cytoplasm and
s figure legend, the reader is referred to the web version of this article.)
Fig. 4. Overexpression of CXCL10 inhibits cell proliferation. Control and
transfected cells were incubated in 96-well plates in triplicates. Cell proliferation
was measured by Cell Titer96 MTS assay. Graphs illustrate Mean±SEM values
averaged for 3 experiments.
Fig. 2. Secretion of CXCL10 by the transfected LNCaP cells. (A) Standard curve
generated for the assay of CXCL10 using ELISA. (B) Transfected cells (1×105
cells in 2 ml medium/well) were seeded in 12-well plates. Media were removed
after various days of cell growth, centrifuged and assayed for CXCL10. Error
bars represent the SD of 3 independent experiments.
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(Figs. 3 and 4). Mibolerone (1 ng/ml) in 1% CS-FCS did not
induce cell proliferation of LNCaP cells in control and
transfected cells (Fig. 3).
3.5. Effect of overexpression of CXCL10 on PSA expression
The expression of CXCL10 was markedly enhanced in the
transfected cells as revealed by RT-PCR (Fig. 5). PSA mRNAFig. 3. Overexpression of CXCL10 inhibits cell growth of human LNCaP
prostate cancer. cells in serum limited medium (1% FCS). At the indicated time
points post-seeding, cells were analyzed by the MTS assay. The data represent
the mean±SEM of quadruplicate wells from 3 independent experiments.
***P<0.0001 vs. respective controls (ANOVA and Dunnett's test).levels increased by 1 nM mibolerone in 1% CS-FCS-medium,
and decreased significantly in the transfected cells as compared
with the controls. PSA expression was quantitated by real-time
RT-PCR (Fig. 6). The PSA mRNA expression in transfected
cells was 30% of that of the control. Mibolerone (1 nM/ml)
induced PSA mRNA levels of the transfected cells were
approximately 60%–70% of that of control cells (Fig. 6D).
3.6. Effect of overexpression of CXCL10 on CXCR3 expression
The enhanced expression of CXCL10 in transfected cells
increased CXCR3 mRNA levels as revealed by RT-PCR (Fig. 7).
The quantification of the gel bands by densitometric measure-
ments estimated the increase by 3–4-fold. Furthermore, flow
cytometry showed the evidence of an increase in CXCR3
expression over the control cells (Fig. 8).
4. Discussion
In this study, we have shown that overexpression of
CXCL10 strongly inhibits LNCaP cell growth, up-regulatesFig. 5. Expression of G3PDH, CXCL10 and PSA in control, vector (pIRES2–
EGFP)- and plasmid (pI2E–CXCL10)-transfected LNCaP cells. Lane Std
indicates standard markers (pGEM, Promega) and the numbers on the left
indicate the sizes of the bands in base pairs. (A) G3PDH; 601 bp. (B) CXCL10;
270 bp. (C) PSA; 360 bp.
Fig. 6. Effect of overexpression of CXCL10 on PSA mRNA expression. (A) Melt-curve data collected after PSA amplification. All wells except the zero template
control produced a single amplification product. (B) The standard curve was prepared with cDNA from LNCaP cells using a set of primers for PSA. The cDNAwas
used in decreasing concentrations with 1:10 dilutions in triplicates. (C) A plot of the threshold cycle number as a function of the input target quantity shows a linear
relationship. (D) PSA/G3PDH mRNA levels in treated and untreated cells. After medium change, LNCaP cells (control, vector-transfected, plasmid-transfected) were
treated with mibolerone (1 ng/ml) and cultured for 24 h. The values represent the mean±SEM of the combined samples from 3 experiments each with 3 replicates.
***P<0.0001 vs. respective controls.
Fig. 7. Activation of CXCR3 expression by overexpression of CXCL10. Total
RNA was extracted from control (lane 1), vector (IRES2–EGFP)-transfected
(lane 2) and CXCL10 transfected (pI2E–CXCL10) (lane 3) LNCaP cells, and
subjected to RT-PCR. (A) EGFP, 366 bp; (B) CXCL10, 270 bp and (C) CXCR3,
280 bp.
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proliferation properties of CXCL10 in prostate cancer cells
have not yet been described. We have utilized a vector,
pIRES2–EGFP developed by Clontech, Inc, to overexpress
human CXCL10 in LNCaP prostate cancer cells. This vector
contains the internal ribosome entry site (IRES) of the
encephalomyocarditis virus (ECMV) and the enhanced green
fluorescent protein (EGFP). This permits both the gene of
interest and the EGFP to be translated from a single bicistronic
mRNA, but the resultant gene products are separate proteins,
and not a fusion protein. We demonstrated that overexpression
of CXCL10 inhibited cell growth and PSA production in
LNCaP cells. The efficiency of this system has been reported
previously by several investigators [13,14]. Transient over-
expression of IRES–GFP constructs of PDGF resulted in the
proliferation of senescent cardiac fibroblasts via AKT kinase
[13]. Overexpression of E2F2 in pIRES2–EGFP resulted in
Fig. 8. The CXCR3 expression was analyzed by FACS. Cells were stained with both antibodies, primary and PE-conjugated secondary. Black line, unstained; Green
line, EGFP +ve; and Red line, CXCR3 +ve cells. Panel A, Control LNCaP cells; Panel B, pI2E–CXCL10 transfected LNCaP cells. This is a representative of 4 similar
experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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and cyclin B1 (a 2–3-fold increase) in rabbit corneal
endothelial cells than in the control cells [14]. We have
reported previously that overexpression of CXCL10 in MA-10
mouse Leydig tumor cells inhibited cell proliferation [15].
It is now becoming clear that chemokines are not just
leukocyte chemoattractants, but play pleiotropic roles in
cellular transformation, tumor growth, invasion and homing,
metastasis and immune modulation. CXCL10 is a member of
the chemokine family. This family is divided into 4
subfamilies; CXC, CC, C and CX3C [16]. The CXC in
CXCL10 protein is CysAsnCys. The human CXCL10 gene
consists of 4 exons. It yields a single band of 1.5 kb mRNA
by Northern blotting [9,17]. Human CXCL10 cDNA encodes
99 amino acid residue precursor protein with a 22 amino acid
residue signal peptide that is cleaved to form 77 amino acid
residue secreted protein with a molecular weight of 8.7 kDa
[17]. The mechanism of action of CXCL10 is believed to be
mediated by its binding to cell surface receptors, such as
CXCR3, heparan sulfate glycosaminoglycan (GAG) and
unknown receptors [7,18,19]. The human CXCR3 cDNA
has an open reading frame of 1104 bp encoding a protein of
368 amino acids with a molecular mass of 40,659. The
sequences include seven putative transmembrane segments
characteristic of G-protein coupled receptors (GPCR). CXCR3
receptors are coupled to Gαi proteins, making cellular
responses to chemokines inhibitable by pertussis toxin.
Receptor activation inhibits cAMP production, but other
signal transduction pathways (PI3 kinase and MAPK) are
clearly involved as well [20]. Two variants of CXCR3,
CXCR3-A and CXCR3-B were identified by using rapid
amplification of cDNA ends (RACE) and Northern blot
analysis [21]. By transfection studies in human microvascular
endothelial cell line-1 (HMEC-1), it was further observed that
CXCR3-A mediated cell proliferation effects, whereasCXCR3-B mediated antiproliferative effects. Finally, mono-
clonal antibodies raised to selectively recognize CXCR3-B
reacted with endothelial cells from neoplastic tissues,
providing evidence that CXCR3-B is also expressed in vivo
and may account for the angiostatic effects of CXC
chemokines [21]. A variant of CXCR3, termed as CXCR3-
alt, has been cloned from human PBMC cells, whose
expression is considerably lower (∼15-fold) than the full-
size receptor and its function is not known yet [22]. Recently,
it has been shown that the expression of ELR-CXC
chemokines (CXCL10 and CXCL11), which are angiostatic,
is significantly lower in prostate cancer cells (CA-HPV-10
and PC-3) as compared to normal epithelial cells (PZ-HPV-7)
[10]. CXCL10 is a potent chemoattractant for stimulated T
cells and NK cells. Anti-tumor effects of CXCL10 may be
mediated by the recruitment of CD8+ and CD4+ cells to
tumors [23–25]. Furthermore, CXCL10 inhibits angiogenic
processes and antagonizes the effects of basic fibroblast
growth factor (bFGF) and CXCL8 [26,27].
Our results showed that CXCL10 protein secreted in the
medium by transfected cells was 3–6 ng/ml after 6–8 days of
cell culture, whereas the levels of CXCL10 in control cells
were undetectable as estimated by ELISA. Interestingly, the
CXCL10 overexpression caused significant increase in its
receptor CXCR3 expression. Previously, we observed that
overexpression of CXCL10 in MA-10 mouse Leydig tumor
cells significantly increased CXCR3 mRNA and protein
expression [15]. Goldberg-Bittman et al. [28] reported that
unlike many other chemokine receptors, CXCR3 expression
was not down-regulated by exposure to high concentrations
(500 ng/ml) of its ligand, but was rather promoted, which
corroborates our results. CXCL10 induced upregulation of
CXCR3 expression in the three human breast adenocarcinoma
cell lines, which was inhibited by cycloheximide, indicating
that de novo protein synthesis was required for this process.
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tumor cells suggests that a CXCR3–CXCL10 axis may
function in these cells, and paves the way for an in depth
analysis [28]. It has been shown that chemokine receptors are
rapidly desensitized and internalized following ligand binding,
a process that attenuates receptor-mediated responses [29,30].
Known inhibitors of chemokine-induced chemotaxis, such as
pertussis toxin or wortmannin, did not reduce ligand-induced
internalization, suggesting that a distinct signal transduction
pathway mediates internalization [30]. CXCR3–CXCL10 axis
may have a direct role in membrane integrity, as higher
concentrations of CXCL10 are antiproliferative (Our labora-
tory is currently exploring these effects).
In this study, we showed that CXCL10 down-regulated
mobilerone-induced PSA expression. In LNCaP cells, miboler-
one at very low levels (1 nM) increase AR-mediated
transcription of PSA by 50–60-fold [31]. In this regard, the
molecular mechanism(s) by which CXCL10 regulates the
androgen signaling in prostate cells needs to be explored
further. Recent studies have shown that besides AR mutations,
the modulation of the AR protein by phosphorylation,
acetylation, and sumoylation also regulates AR activity [32–
34]. Modulation of the activities of AR cofactors is another
factor that can change PSA transcription [35,36].
Our data showed that overexpression of CXCL10 inhibited
cell proliferation. Our results are in agreement with the previous
reports that CXCL10 inhibits cell proliferation [5,18,37].
CXCL10 is highly effective in the inhibition of primary
human microvascular endothelial cell proliferation [38]. The
growth of CXCL10-transduced melanoma cells was markedly
diminished compared to the parental or null-transduced cells.
They suggested that CXCL10 gene therapy might be an
effective therapy in patients with cancer [39]. Previously, it has
been shown that CXCL10 and MIG mimic the antitumor effects
of IL-12 [40–42]. Neutralizing antibodies to CXCL10 and MIG
partially abrogated IL-12-mediated regression in the RENCA
model [40].
In conclusion, in the present study, we demonstrated that
the expression of CXCL10 by transfection with pIRES2–
CXCL10–EGFP of LNCaP cells was markedly enhanced at
mRNA and protein levels in the cells. Significant levels of
secreted CXCL10 were detected in the spent medium of
transfected cells as measured by enzyme-linked immunosor-
bent assay (ELISA). Overexpression of CXCL10 inhibited cell
proliferation of the transfected cells by 30%–40% in serum-
limited medium (1% FCS in RPMI1640 medium). CXCR3
expression was significantly induced by the overexpression of
CXCL10 as determined by RT-PCR and fluorescence-
activated cell sorting (FACS). Overexpression of CXCL10
inhibited cell proliferation by up-regulation of CXCR3
receptor. CXCL10 may be potentially useful in the treatment
of prostate cancer.
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